natgillin/translations-raw huggingface dataset:
ΟΛΟΝΥΣ C1 C2 C3 C4 C5
Total B
B
Total B
19 9 12 42 -- --
12
23 13 13 37 -- --
13
32 14 14 44 -- --
14
41 15 19 44 4 --
44
ΟΛΟΝΥΣ D1 D2 D3 D4
44
C
C4
63 -- 4 -- --
4
63 1 4 -- --
1
72 1 4 -- --
1
82 1 5 -- --
1
ΟΛΟΝΥΣ
Total D
D
Total D
5
5 5
6
6 6
ΟΛΟΝΥΣ Ν ΕΣΕΘ
TOTAL POSTS TOTAL POSTS
όκιλεΤ EMEA/ MB/ 003/ 01- EL -
32 EMEA Work Programme 2001-2002
ςαδάνο
Allocation of posts
ςιεσέθ
Allocation in 2001
ςαδάνο ςητ
Allocation in 2002
υονέ ατσϊορπ υοτ αδά Ο ύο σινοτνυσ ύοκινχετ αδάνοΜ
Directorate and financial control Administration Unit
36
11
--
11
ςαδάνο
Head of Unit team Sector for Personnel, budget and facilities Sector for Accounting Reserve posts
ολονύΣ
Unit total
10 3
2 22 6 2
--
2 23 6 2
27
33 33
αιελάφσα νητ ιακ ησηνπύργαπεοκα ραφ νητ αιγ ςαέ οΤ ςηξιρήτσοπυ
Unit for the Pre-authorisation Evaluation of Medicines for
22 2
Human Use
ςήκιτωναγρο ιακ νωεσέθοπυ νώκιτσι θυρ ςαέ οΤ ςαδάνο ςητ υονέ ατσϊορπ υοτ αδά Ο
Head of Unit team Sector for Scientific advice and orphan drugs Sector for Quality of medicines Sector for Safety and efficacy of medicines Reserve posts
ολονύΣ
Unit Unit total
19
2 12 19 16 --
13 2
2 13 21 21 --
12 2
57 57
νώκινο ητσιπε ήχοραπ νητ αιγ ςαέ οΤ ςαδάνο ςητ υονέ ατσϊορπ υοτ αδά Ο ςαιεδά
Unit for the Post-authorisation Evaluation of Medicines for Human Use
ςησηγήροχ ςητ ιατίεγηορπ υοπ ησήρχ ηνιπώρθνα αιγ νωτνόϊορπ νώκιτυεκα ραφ ησηγόλοιξα νητ αιγ αδάνοΜ 33
Head of Unit team Sector for Regulatory affairs and organisational support Sector for Pharmacovigilance and post-authorisation safety and efficacy of medicines Reserve posts Unit totalUnit total Unit for Veterinary Medicines and Information Technology
32 2
2 24 32 4 62 62
ςαδάνο
3 9 7 17 -- 36 36
ολονύΣ
3 10 8 20 1 42 42
ςιεσέθ ςέκιρδεφΕ
4 15 12 10 -- 41 41
6 6
4 16 13 12 -- 45 45
ςήκιτσιγολ ςαέ οΤ νωεσάτσατακγε
Additional posts in general reserve
23
--
22
220
ιακ
251
ύο σιγολοπϋορπ ύοκιπωσορπ ςαέ οΤ,
EMEA Work Programme 2001-2002
2
33
2
Annex 2 EMEA budget summaries 2000-2002
11
2000 (1)
11
2001(2)
2002
2002 (3)
οτ ή οναταΚ
(3 1.12.2000)
οτ ή οναταΚ
(21-22.2.2001)
ύοκιπωσορπ ή οναταΚ
(21-22.2.2001)
ητράρ
Revenue
αΠ
fees
α 2
39 154 000
σιγολοπϋο ρπ ίο κιτπο νυΣ 2002
70.82%
υο τ ίο
42 610 000
EMEA
68.56%
οδοίρεπ νητ αιγ
46 521 000
2000 –
66.13%
οτ αιγ ίο σιγολοπϋορπ ίοκιτπονυσ ίοκιτιρκγυσ ιΟ
general EU contribution
2000
13 200 000
οτ ιρχέ
23.88%
2002
14 700 000
:
23.64%
ςήξε ςω νυοχέ (
15 500 000
)
22.04%
ώρυε εΣ
special EU orphan medicinal product contribution
2000( 1)
1
2001( 2)
000 000
2002( 3)
1.81%
39. 154. 000
600 000
70, 82%
0.97%
42. 610. 000
3 943 000
68, 56%
5.6 1%
46. 521. 000
contribution from EEA
66, 13%
245 220
ατ αιγ
0.44%
13. 200. 000
250 000
23, 64%
0.40%
15. 500. 000
250 000
22, 04%
0.36%
ακα ράφ άναφρο ΧΟΕ νοτ όπα άροφσιενυΣ
contribution from EU programmes (PERF)
1. 000. 000 245. 220
2 17 000
1, 81% 0, 44%
0.39%
600. 000 250. 000
2 658 000
0, 97% 0, 40%
4.28%
3. 943. 000 250. 000
2 627 000
5, 61% 0, 36%
3.74%
(PERF)
other
ΕΕ ςητ
1
217. 000
471 000
4, 28%
2.66%
2. 627. 000
1 334 000
3, 74%
2.15%
1. 471. 000
1 491 000
2, 66%
2.12%
1. 334. 000
55 287 220 55 287 220
2, 15%
100.00% 100.00%
1. 491. 000
62 1 52 000 62 152 000
2, 12%
100.00%
Ν ∆ΟΣΕ ΟΛΟΝΥΣ
70 332 000 70 332 000
55. 287. 220
100.00%
62. 152. 000 100, 00%
Expenditure Staff
70. 332. 000
18 493 000
100, 00%
33.45%
ςενάπα∆ όκιπωσορΠ
21 772 000
ίοθσιΜ
35.03%
18. 493. 000
24 842 000
33, 45%
35.32%
21. 772. 000 35, 03%
interim and other support persons
24. 842. 000
1 058 000
35, 32%
1.91%
1. 058. 000
1 379 000
1, 91%
2.22%
1. 379. 000
1 413 000
2, 22%
2.01%
1. 413. 000
1 350 000
2, 01%
2.44%
1. 350. 000
1 501 000
2, 42%
2.42%
1. 622. 500
1 622 500
1
total title 1 1
20. 901. 000
Total title
24. 652. 000
20 90 1 000 20 901 000
39, 67%
39.80% 39.80%
27. 877. 500
24 652 000 24 652 000
39, 64%
39.67% 39.67%
5. 212. 220 2. 423. 500
27 877 500 27 877 500
9, 43% 4, 38%
39.64%
9, 15% 2, 25%
39.64%
5. 450. 000 1. 200. 000
Building/equipment
7, 74% 1, 71%
rent/charges
2. 353. 000 480. 000
5 212 220
4, 26% 0, 87%
9.43%
824. 500 537. 000
5 685 000
1, 33% 0, 86%
9.15%
1. 389. 500 577. 000
5 450 000
1, 98% 0, 82%
7.74%
ςενάπαδ ςέκιτηκιοιδ ςέπιοΛ
expenditure on data processing
1. 593. 000
2 423 500
2, 88%
4 .38%
1. 784. 500
1 400 000
2, 87%
2.25%
1. 947. 500
1 200 000
2, 77%
1.71%
υοίαλαφεκ ολονύΣ ςαίγρυοτιελ ςενάπα∆
other capital expenditure
10. 231. 000
353 000
16, 46%
4.26%
10. 564. 000
824 500
15, 02%
1.33%
ςιεσάιρδενυΣ ςιεσήγο λοιξΑ ησαρφάτεΜ
1
5, 92% 33, 79% 0, 00%
389 500
6, 64% 31, 63% 0, 69%
1.98%
4. 363. 000 24. 107. 500 467. 000
postage and communications
180. 000
480 000
0, 29%
0.87%
100. 000
537 000
0, 14%
0.86%
150. 000
577 000
0, 27%
0.82%
220. 000
1 593 000
0, 35%
2.88%
226. 000
1 784 500
0, 32%
2.87%
ΕΕ ατα άργορΠ
1 947 500
217. 000
2.77%
0, 39%
Total title 2 2
2. 658. 000
Total title
4, 27%
21.82% 21.82%
2. 627. 000
10 231 000 10 231 000
3, 74%
16.46% 16.46%
υοίαλαφεκ ολονύΣ
10 564 000 10 564 000
3
15.02%
22. 324. 500
15.02%
40, 38%
meetings
27. 051. 000
3 270 000
43, 87%
5.9 2%
31. 890. 000
4 125 000
45, 34%
6.64%
70. 332. 000
4 363 000
100, 00%
6.20%
αδίλεΣ
evaluations
49/ 65
18 682 500
50/ 65
33.79%
.
19
2002:
658 000
(3)
31.63%
.
24
2000:
107 500
51/ 65
34.28%
όκιλεΤ
translation
Ο
p.m.
EMEA
0.00%
Ο
428 000
EMEA
0.69%
Noël WATHION
467 000
Ο
0.66%
EMEA υοτ ιακ νώχρα EMEA.
studies and consultants
»)
5 000
(«
0.01%
EMEA
180 000
EMEA
0.29%
νοτ
100 000
52/ 65
0.14%
αδίλεΣ
publications
όκιλεΤ
150 000
EMEA.
0.27%
αδίλεΣ
220 000
όκιλεΤ
0.35%
αδίλεΣ
226 000
όκιλεΤ
0.32%
(EDIR/ 016/ 1997)
EU programmes
υοίρβ
217 000
ΑΕΜΕ
0.39%
)
2
ΑΕΜΕ
658 000
EMEA
4.27%
L - 2985 2, rue de Mercier
2
ογρύοβ εξυοΛ
627 000
1) οτ αιγ νωτά σελετοπα νωτ ιακ
3.74%
:
total title 3 3
νητ όπα ιατνεθίταιδ ςαδίρε ηφΕ
Total title
νώκιλετ νωτ νωνέ οναβ αλιρεπ υσ
22 324 500 22 324 500
1998 (
40.38% 40.38%
οτ αιγ νωεσώτσιπ 1999
27 051 000 27 051 000
2000,
43.87% 43.87%
ςοτέ όκι ονοκιο οτ αιγ
3 1 890 000 31 890 000
σ
45.34%
υοτ νώναπαδ ιακ νωδόσε ςό σιγολοσΙ ςητ ΕΕ ακα ράφ άναφρο
TOTAL EXPENDITURE TOTAL EXPENDITURE
EMEA
100.00% 100.00%
ατ αιγ
62 152 000 62 152 000
υοίρβ εκε∆ ςη ςητ υοίλυοβ υΣ υοτ ιακ υοίλυοβονιοΚ ύοκϊαπωρυΕ υοτ
100.00%
(L 18
100.00%
22. 1. 2000,.
70 332 000 70 332 000
1)
100.00%
1999
100.00%
141/ 2000
Notes (1) 2000 budget: final appropriations.
νωκά ραΦ ςησηγόλοιξΑ ό σιναγρΟ όκϊαπωρυΕ νοτσ ιατνολλάβατακ υοπ ηλέτ ατ ε άκιτεχσ
34 EMEA Work Programme 2001-2002
3)
Annex 3 EMEA contact points and reference documents
(
EMEA contact points
ύο σινονακ υοτ ησηίοποπορτ νητ αιγ
For enquiries concerning certificates for centrally authorised medicines for human or veterinary use
υοίρβ εκε∆ ςη ςητ υοίλυοβ υΣ υοτ
Pharmacovigilance and product defect reporting The constant monitoring of the safety of medicines after authorisation (‘pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA.
2743/ 98
The EMEA receives safety reports from within the EU and outside
1)
Contact points Jonna SUNELL-HUET Direct telephone (44-20) 74 18 84 65 E-mail: certificate@emea.eudra.org
ΕΕ εκηθήιοποπορτ ςωπό ακα ράφ άκιρταινητκ ατ ε άκιτεχσ νώλε L 317 (,
concerning centrally authorised medicinal products and coordinates action relating to the safety and quality of medicinal products.
νώταρκ νωτ νώισεθο ον νωτ ησιγγέσορπ νητ αιγ
Documentation services A wide range of documents has now been published by the EMEA, including press releases, general information documents, annual reports and work programmes.
υοίρβ ετπεΣ
These and other
ςη ςητ υοίλυοβ υΣ υοτ ΚΟΕ 1981 28
For matters relating to pharmacovigilance for medicinal products for human use Contact point
ΕΕ εκηθήιοποπορτ ςωπό ατα σάυεκσοιδι άκιτυεκα ραφ νύοροφα υοπ νωεξάταιδ νώκιτηκιοιδ
documents are available either on the Internet at http://www.emea.eu.int or by writing to:
ιακ νώκιτσινονακ νώκιτεθο ον νωτ ςωεσίγγεσορπ ίρεπ
Noël WATHION Direct telephone (44-20) 74 18 85 92 E-mail: noel.wathion@emea.eudra.org
υοΐαΜ ςή ςητ υοίλυοβ υΣ υοτ ΚΟΕ
Subscription Service European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf
ςωπό ςησυελέορπ ςήκιωζ α ιφόρτ εσ νωκά ραφ νώκιρταινητκ νωπίολατακ νωίρο νωτατώνα ό σιροθακ νοτ,
For matters relating to pharmacovigilance for medicinal products for veterinary use Contact point Barbara FREISCHEM Direct telephone (44-20) 74 18 85 81 E-mail: barbara.freischem@emea.eudra.org For product defect and other quality-related matters Contact point Francisco PEÑARANDA FERNANDEZ Fax number for defective product rapid alerts (44-20) 74 18 85 90
αιγ ςαίσακιδαιδ ςήκιτονιοκ ησιπσέθ ητ αιγ
UK - London E14 4H A subscription service is available for all EMEA public documents, distributing documents electronically or in paper form.
υοίνυοΙ ςη ςητ υοίλυοβ υΣ υοτ 1990 26
Further information can be obtained from the above address or from Contact point Iro MAVROPOULOS Direct telephone (44-20) 74 18 85 82 E-mail: subscriptions@emea.eudra.org
ΕΕ εκηθήιοποπορτ ςωπό νωτνόϊορπ νώκιτυεκα ραφ ησηγόλοιξα νητ αιγ ύο σιναγρο ύοκϊαπωρυε
E-mail: francisco.penaranda@emea.eudra.org Certificates of a medicinal product The EMEA issues certificates of a medicinal product in conformity with the arrangements laid down by the World Health Organisation.
ησατσύσ ητ αιγ ιακ ησήρχ ήκιρταινητκ ιακ ηνιπώρθνα αιγ νωτνόϊορπ νώκιτυεκα ραφ νωτ ςαίετποπε ιακ ςησιρκγέ
These certify the marketing authorisation and good manufacturing status of medicinal products in the EU and are intended for use in support of marketing authorisation applications in and export to non-EU countries.
νώισακιδαιδ νώκιτονιοκ ησιπσέθ νητ αιγ
Requests for general information packs should be sent to Contact point Amanda BOSWORTH Direct telephone (44-20) 74 18 84 08 E-mail: amanda.bosworth@emea.eudra.org
θιρα ΚΟΕ ςό σινοναΚ.
EMEA Work Programme 2001-2002
)
35
(
European experts lists The list of European experts is available for examination on request at the EMEA offices.
ΕΕ ςητ ςιεσόδκε ςε ησίπΕ 55/ 65
Requests may be made either in writing to the EMEA or sent to the following e-mail addresses:
ςαίσαγρε α αργόρΠ 2001- 2002
Human medicines’ experts list human_experts@emea.eudra.org
EMEA/ MB/ 003/ 01- EL - UK - London E14 4HB Canary Wharf 7 Westferry Circus European Agency for the Evaluation of Medicinal Products Sector for Document management and publishing ησνυθύειδ ωρέτωτακ νητσ ςωφάργγε ςοτνέθηλβοπυ ςοτα ήτια: νιπότακ ςυονέ ορεφαιδνε ςυοτσ ςώκι ορδυχατ νύολατσοπα αν νύοροπ ετίε
EU official publications • Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products, as amended (OJ L 214, 24.8.1993, p.
.
1)
νοτ όπΑ ςήτνυθυειδ ςόκινεγ ςήτωρηλπανα ςω αρετόγρα ιακ νωεσήριεχιπε ςήτνυθυειδ ςω άκιχρα.
Veterinary medicines’ experts list vet_experts@emea.eudra.org Inspectors’ experts list inspectors_experts@emea.eudra.org
1990
• Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as amended (OJ L 224, 18.8.1990, p.
1994.
1)
1982οτ όπα άντειΒ οτσ ςαίεγυ ςαίσαγρενυσ α αργόρπ όκιδηυοσ οτ αιγ ςολυοβ ύσ ςόκιτυεκα ραφ ςορετώνα εσελέτει∆ άκιτπηλλυσιτνα ατ ιακ άκιτωκραν ατ ςέυεκσυσ ςέκιρται ςιτ άκιτνυλλακ
For general information
ατ ατνόϊορπ άκιτυεκα ραφ άκιτυφ ατ αιγ ςονυθύεπυ νατή οίοπο οτ άτακ α ητσάιδ
• Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products, as amended (OJ L 147, 9.6.1975, p.
,
Contact points Martin HARVEY Direct telephone (44-20) 74 18 84 27 E-mail: martin.harvey@emea.eudra.org
ςωέ οτ όπα ςαίδηυοΣ ςητ ςαιονόρΠ ιακ ςαίεγΥ οιλύοβ υΣ όκινθΕ οτσ εχίετε υσ
approximation of the laws of Member States relating to veterinary medicinal products, as amended (OJ L 317, 6.11.1981, p.
Ο αλάψυΟ ςητ οι ήτσιπεναΠ οτσ ςαροτκέλ
1) • Council Regulation (EC) No 2743/98 of 14 December 1998
οτ ςωέ
Antoine CUVILLIER
οτ όπΑ αρε ήσ ιρχέ 1978,
amending Council Regulation (EC) No 297/95 on fees
αί ορδοιδατΣ 1976
Direct telephone (44-20) 74 18 84 28
ςαίεγυ ςοτα ήτσυσ υοτ
payable to the European Agency for the Evaluation of
αί ονοκιο νητσ ιακ ησηκίοιδ ητσ ςέδυοπσ ςέκαιχυτπατεΜ ήκιτυεκα ραφ ήκιτσινονακ ιακ ήκινωνιοκ.
E-mail: antoine.cuvillier@emea.eudra.org For matters concerning medicinal products for human use Contact point
MSc
•
ςατητόοκηπυ ςήκιδηυοσ
Medicinal Products (OJ L 345, 19.12.1998, p.
16
1)
ςιτσ ςίεθηννεγ ςήτνυθυει∆ ςόκινεΓ,
Noël WATHION Direct telephone (44-20) 74 18 85 92 E-mail: noel.wathion@emea.eudra.org
οτ όπα ΑΕΜΕ υοτ οιλύοβ υσ όκιτηκιοιδ οτσ ιεχέτε υσ 1996
EMEA budget statement for the financial year 2000, including final appropriations for 1999 and outturn for 1998 (OJ L 184, 24.7.2000, p.
υοτ ολτίτ νοτ εβαλΈ αιδίταρκ αδνοπσό ο αέν ατσ
The texts of these and other provisions are available in the For matters concerning medicinal products for veterinary use
νώισερηπυ νώκιρταινητκ νωτ ησωρθράιδανα νητσ εχίετε υσ
These publications, along with copies of the
οτ ιακ νωτνόϊορπ
Contact point
νώκιτυεκα ραφ 1990
Official Journal, are available from:
νώκιρταινητκ αέ οτ νοτ αιγ αιδό ρα ιανίε υοπ ςησνυθύειδ ςητ ςηνέ οναβ αλιρεπ υσ ςιεσέθ
Peter JONES Direct telephone (44-20) 74 18 84 13 E-mail: peter.jones@emea.eudra.org
ςεροφάιδ εσ ςαίεγΥ οίεγρυοπΥ όκαιδνοπσο Ο όκινα ρεΓ οτσ εκηθσάγρε
Office for Official Publications of the European Communities 2, rue de Mercier L - 2985 Luxembourg
οτ όπΑ οτ
36 EMEA Work Programme 2001-2002
οτσ εκηθσάγρε οτ όπΑ οτ
and also on the EudraLex Internet site at http://pharmacos.eudra.org/eudralex/index.htm
1975
EMEA documents • First General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1995 (ISBN 92-827-7491-0, Office for Official Publications of the EU) • Second General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1996 (ISBN 92-9155-002-7, Office for Official Publications of the EU) • Third General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1997 (ISBN 92-9155-010-8, Office for Official Publications of the EU) • Fourth General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1998 (ISBN 92-9155-018-3, Office for Official Publications of the EU) • Fifth General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1999 (ISBN 92-9155-026-4, EMEA) • Sixth General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 2000 (ISBN 92-9155-034-5, EMEA) • Statement of principles governing the partnership between the national competent authorities and the EMEA (EMEA/MB/013/97) • Financial Regulation applicable to the budget of the EMEA (EMEA/MB/011/97) • Decision of the Executive Director of 3 December 1997 on rules on access to documents of the EMEA (EDIR/016/1997) • Decision of the Executive Director of 1 June 1999 on cooperation with the European Anti-Fraud Office (OLAF) (EDIR/006/1999) • Catalogue of EMEA public documents (updated regularly) • EMEA Code of Conduct (EMEA/D/37674/99)
όπα ςαίνοξαΣ ωτάΚ ςητ αίσερηπυ ήκιτηκιοιδ ήκιρταινητκ νητσ ιακ
These and other documents are available either on the Internet at http://www.emea.eu.int or by writing to:
ςιεδώΙ ςιτ αιγ ορτνέΚ όκιτηνυερΕ όκαιδνοπσο Ο όκινα ρεγ οτσ εκηθσάγρε
Sector for Document management and publishing European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf UK - London E14 4HB
Kothmann
EMEA Work Programme 2001-2002
:
Annex 4 Profiles of EMEA personalities
ςατητόοκηπυ ςήκινα ρεγ
Keith Jones, Chairman of the Management Board, b.
1943,
14 October 1937, n.
υοίλυοΙ
British
23
23 July 1943, n.
ςιτσ ςίεθηννεγ υοίλυοβ υσ ύοκιτηκιοιδ υοτ ςορδεόρπιτνΑ, οτ υοίλυοβ υσ υοτ ςορδεόρπ εκηθχέλκε ιακ
He then trained as a toxicologist in the agrochemical industry.
Gerhard Kothmann,
Education:
2001.
Career to date:
οτ ΑΕΜΕ
Career to date:
1995
Dr Jones joined the EMEA Management Board in 1995 and was elected chairman of the Board in 2001.
υοτ υοίλυοβ υσ ύοκιτηκιοιδ υοτ ςολέ ενιγέ
in 1970 and the veterinary administrative service for Lower Saxony in 1972.
υονίδνοΛ υοτ υοί ητσιπεναΠ υοτ ήλοχσ ήκιτυεκα ραφ ητσ ςαίγολοκα ραφ ςήτηγηθακ ςητπέκσιπε ιανίε αρε ήΣ νώτωλανατακ νωτ αίσατσορπ νητ ιακ αίεγυ αισό ηδ ητ αιγ ςήπορτιπΕ ςήκϊαπωρυΕ. ςητ ςησνυθύει∆ ςήκινεΓ ςητ ςήπορτιπε ςήκιτσινοτνυσ ςήκινο ητσιπε ςητ ςολέ ιακ ςώθακ ΕΕ ςητ ήπορτιπε ήκιτσι θυρ η ινό ητσ ιακ ήπορτιπε ήκιτυεκα ραφ ητσ υοίελισαΒ υονέ ωνΗ,
He moved to the German Federal Ministry for Health in 1975 where he has served in various posts, including in the division responsible for veterinary pharmaceutical sector, and in 1990 he collaborated in the reconstruction of the veterinary services in the new federal Länder.
υοτ ςοπωσόρπιτνα ιανίε αρε ήσ ιακ υοίελισαΒ υονέ ωνΗ υοτ νωκά ραΦ υοχγέλΕ ό σιναγρΟ
He was appointed Chief Veterinary Officer in 1991.
νοτσ ςήτνυθυειδ ςόκινεγ εκητσίροιδ
Dr Kothmann joined the EMEA Management Board in 1996 and was elected vice- chairman in 2000.
οΤ ΑΠΗ ςιτσ
Thomas Lönngren, Executive Director, b.
Merck Sharp and Dohme
16 December 1950, n.
νητσ
Swedish
Jones
Education:
νωεσέθοπυ νώκιρται ςήτνυθυειδ ςόκινεγ ιακ
Qualified pharmacist from the University of Uppsala Faculty of Pharmacy.
νητσ ςαίγολοκα ραφ
MSc in social and regulatory pharmacy.
νητσ ςοτα ή τ ύοκιρται υοτ Fisons Agrochemical Divisions,
Post-graduate studies in management and health economics.
ρ∆ Ο αρε
Career to date:
Jones 22
From 1976 to 1978, lecturer at University of Uppsala.
νωτνόϊορπ νώκι ηχοργα νωτ οδάλκ νοτσ ςογόλοκιξοτ. ςω εκητύεδιαπκετεΜ υοίελισαΒ υονέ ωνΗ υοτ αίε οκοσον άκαι ητσιπεναπ εσ ςανυερέ ιακ.
He acted as senior pharmaceutical consultant for the Swedish health cooperation programme in Vietnam from 1982 to 1994.
ςήκιρται ςήκινιλκ ςιεσέθ εσ ιεσέλεταιδ ιεχέ ιακ ςήκιρται ςοχύοιχυτπ
He joined the Swedish Medicinal Products Agency in 1990, serving as Director of Operations and later as Deputy Director-General.
ιανίε ςατητόοκηπυ
EMEA scientific committees
ρ∆ Ο ησυεδίαπκΕ ςήκινατερβ
Daniel Brasseur, Chairman of the CPMP, b.
Jones
7 June 1951, n.
1937,
Belgian
υοίρβωτκΟ
Eric Abadie, Vice-Chairman of the CPMP, b.
14
14 July 1950, n.
Keith Jones,
French
EMEA
Education:
υο τ νώχελετσ νώ κισαβ νω τ ατα
Post-graduate degree in paediatrics and a PhD in nutrition.
ώ ιε
Education:
ησ άκιφαργοιβ α
Qualified medical doctor from the University of Paris.
ο τνύΣ
He also holds an MBA.
57/ 65
Career to date:
αδίλεΣ
From 1976
ητράραΠ ςαίσαγρε α αργόρΠ 2001- 2002
to 1986 Dr Brasseur worked as a
όκιλεΤ EMEA/ MB/ 003/ 01- EL - αδά ο νητσ ιακ
paediatrician at the University Sint Pieter Hospital in Brussels.
ύο σιναγρΟ ύοκιρταινητΚ ύοκιλλαΓ υοτ νωτνόϊορπ νώκιτυεκα ραφ ςησηγόλοιξα
He jo ined the Pharmaceutical Inspectorate of the Belgian Ministry of Public Health as head of medical assessors in 1997.
ςαδάνο ςητ ςονε άτσϊορπ εκητσίροιδ
He was appointed a member of the CPMP in 1997.
οΤ ςαδάνο ςήκαιρητσαγρε ςονυθύεπυ ςησίπε εσελέτει∆ 1997.
Dr Brasseur has held a number of teaching posts and is currently professor of nutrition and related diseases at the Free University of Brussels.
ςαίροφολκυκ νώιεδα ςησηγήροχ νωλέκαφ νωτ ςήτηγησιε ιακ ςανο ώνγοριεπ ε ςω
From 1981 to 1983 Dr Abadie held a number of clinical and laboratory positions, before joining the pharmaceutical industry in 1983.
ςητ ςήκιρταινητΚ οιρήτσαγρΕ οτσ ιατεζάγρε αν εσιχρά
He joined the French medicines agency in 1994 as director of pharmacotherapeutic evaluation, a post he holds today.
οΤ νόυΛ ςητ νώδιεοοΒ
Dr Abadie has been a consultant in cardiology and diabetology since 1984.
ςαίγολοθαΠ 1984,
Gérard Moulin, Vice-Chairman of the CVMP,
οιρήτσαγρΕ οτσ εκητσάγρε
Steve Dean, Chairman of the CVMP, b.
ρ∆ ο
2 August 1951, n.
οτ ςωέ.
British Education:
Moulin
Career to date:
οτ όπΑ αρε ήσ ιρχέ αί ορδοιδατΣ 1984, 1981
During his employment with industry he worked in a variety of product areas including anthelmintics, hormones, growth promoters and veterinary immunology.
νόυΛ ςητ οι ήτσιπεναΠ οτ όπα αίγολοιβορκι ητσ όκιροτκαδι∆ ησυεδίαπκΕ
He is currently Director of Licensing at the Veterinary Medicines Directorate in the UK and is a past Chairman of the Veterinary Mutual Recognition Facilitation Group.
ςατητόοκηπυ ςήκιλλαγ
He was appointed a member of the CVMP in August 1999.
1958,
b.
18
18 October 1958, n.
ςιτσ ςίεθηννεγ
French Education:
ςητ ςορδεόρπιτνΑ
PhD in Microbiology from the University of Lyon Career to date:
υοτ οτσυογύΑ νοτ
From 1981 to 1984, Dr Moulin worked in the Bovine Pathology Laboratory in Lyon.
ςητ ςολέ εκητσίροι∆
In 1984, he joined the Veterinary Medicines Laboratory in Fougères where he was assessor and rapporteur for marketing authorisation dossiers.
ςησιρώνγανΑ CVMP
He was also responsible for a laboratory unit.
ςωπό νωτνόϊορπ ςείρογητακ ςεροφάιδ ε εκηθήλοχσα αίναχη οιβ ητσ υοτ ςήσηλόχσαπα
In 1997 he was appointed as Head of the pharmaceuticals assessment unit of the French veterinary agency (AFSSA-ANMV).
υονίδνοΛ υοτ
Since 1997 he is an active participant in the CVMP and VMRF group.
ςατητόοκηπυ
EMEA Work Programme 2001-2002
:
39
1951, υοτσύογυΑ ςιτσ ςίεθηννεγ
Josep Torrent i Farnell, Chairman of the COMP, b.
2
2 May 1954, n.
. ιακ
Spanish
εσελέτειδ αρετόγρΑ
Yann Le Cam, Vice-Chairman of the COMP, b.
15
15 July 1961, n.
Le Cam
French
αίλλαΓ
Education:
2000, Jouy- en- Josas,
Education:
Centre de Perfectionnement aux Affaires, Groupe HEC- CPA,
He also holds an MBA from the Centre de Perfectionnement aux Affaires, Groupe
οτ όπα ΑΒΜ ςοχοτάκ ςησίπε ιανίΕ
Specialist
Institut Supérieur de Gestion
in internal medicine and clinical
ςατητόοκηπυ
HEC-CPA, 2000, Jouy-en-Josas, France.
ςήκιλλαγ
pharmacology.
υοίλυοΙ
Doctorate in clinical pharmacology from the Career to date:
15
Mr Le Cam has 15 years of professional Autonomous University of Barcelona (UAB). experience and personal commitment in health and medical Career to date:
COMP, ςε ήτσιπΕ
From 1977-1990, Prof.
ςητ ςορδεόρπιτνΑ ςιτ ιακ
Torrent i Farnell worked in internal medicine and clinical pharmacology in Spain and was Assistant Professor of Pharmacology at UAB.
υοτ οιρβ έοΝ νοΤ ακα ράΦ άναφρΟ ατ αιγ ςήπορτιπΕ ςητ ςορδεόρπ εκητχέλκε
From 1990 to 1994, he was Technical Counsellor in Clinical Evaluation and Pharmacology at the Spanish Ministry of Health, Member of the CPMP Efficacy Working Party and involved in the Efficacy Group of the ICH.
1999- 2000. αίτειδ ητ άτακ νωκά ραΦ ύο σιναγρΟ ύοκιναπσΙ υοτ ςήτνυθυειδ ςόκινεγ ιακ νωκά ραΦ ό σιναγρΟ όκιναπσΙ νοτ αιγ ύο σινοτνυσ ςήτνυθυειδ εσελέτειδ
In 1992, he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters/Diploma course on European Registration of Medicinal Products (UAB).
οτ όπα ιακ ςοληλλάπυ ςόκιτηκιοιδ ςόκινο ητσιπε ςοιρύκ ςω
He joined the EMEA in 1995 as Principal Scientific Administrator and from 1996 to 1998 he was Head of Sector for new chemical substances.
1998
In 1998 he was coordinator Director for the creation of the Spanish Medicines Agency and Executive Director of the Spanish Medicines Agency from 1999-2000.
νητ αιγ
He was elected Chairperson of the Committee for Orphan Medicinal Products in May 2000.
υοτ αδά ο νητσ εχίετε υσ ιακ ατητόκιτα σελετοπα νητ αιγ ICH
In November 2000, he became Director-General of the Advanced Centre of Services and Training for Health and Life Sciences, Dr.
ςατητόοκηπυ
Rober Foundation (UAB).
ςητ ςορδεόρΠ
40 EMEA Work Programme 2001-2002
υοτ οιράυοναΙ νοΤ ΑΕΜΕ νοτ αιγ ιατεζάγρε 2001
research non-governmental organisations in France, Europe and the United States in the fields of cancer, AIDS and genetic diseases.
1992
He served as Director-General of AIDES Fédération Nationale from 1992 to 1998.
. ςαίλλαΓ ςητ ςαίεγΥ υοίεγρυοπΥ υοτ ςήκιτυεκα ραΦ ησνυθύει∆ ητσ αιεχένυσ ητσ ιακ οίε οκοσον
He later joined the French Neuromuscular Diseases Association (AFM) as Special Advisor to stimulate public health policy on rare diseases, to create the French Alliance Maladies Rares, a national umbrella organisation of 70 patients associations, and to advise the European Organisation for Rare Disorders (Eurordis), based in Paris.